afatinib,bevacizumab
roche,boehringer ingelheim
['sclc', 'beva', 'bevacizumab', 'nsclc', 'afatinib']
afatinib + bevacizumab vs afatinib as first-line treatment of patients with egfr-mutated advanced non-squamous nsclc: primary analysis of the multicenter, randomized, phase ii study: mpfs 16.3m afabev vs 16.1m afa, hr 0.865 (95%ci, 0.539 1.388 #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis